PILA PHARMA AB Logo

PILA PHARMA AB

Clinical-stage biopharma developing a first-in-class oral drug for diabetes and obesity.

PILA | ST

Overview

Corporate Details

ISIN(s):
SE0015988274
LEI:
6488Z7WG18Q0ZN0V0262
Country:
Sweden
Address:
Norra Vallgatan 72, 211 22 Malmö
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

PILA PHARMA AB is a clinical-stage biopharmaceutical company focused on developing a potential first-in-class oral treatment for metabolic diseases, primarily type 2 diabetes and obesity. The company's lead candidate, XEN-D0501, is a TRPV1 antagonist, representing a novel therapeutic approach with a different mechanism of action compared to mainstream treatments. The company's strategy emphasizes the development of a convenient oral tablet to address the large global patient population. PILA PHARMA is actively advancing its clinical program, with a recent strategic focus on dedicated obesity studies aimed at generating a comprehensive data package to facilitate future partnerships.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all PILA PHARMA AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for PILA PHARMA AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Medivir Logo
Clinical-stage pharma firm developing tumor-directed therapies for high-need cancer patients.
Sweden MVIR
Sweden MBOLIC
Milton Essex Spolka Akcyjna Logo
Develops AI-powered, non-invasive systems for allergy diagnostics & personalized medicine.
Poland MTN
Molecular Partners AG Logo
Pioneering DARPin protein drugs for complex diseases in oncology and virology.
Switzerland MOLN
MorphoSys AG Logo
Biopharma company creating antibody therapies for oncology, with a focus on blood cancers.
Germany MOR
Mycodern Spolka Akcyjna Logo Poland MCD
N4 PHARMA PLC Logo
Developing a nanoparticle delivery system for advanced gene and vaccine therapies.
United Kingdom N4P
NextGen Biomed Ltd. Logo
R&D of biotech medical devices for diabetes care and topical skin treatments.
Israel NXGN
Nicox S.A. Logo
Developing innovative ophthalmology drugs for glaucoma and ocular hypertension.
France COX
ONCIMMUNE HOLDINGS PLC Logo
Antibody biomarker discovery platform for pharma and biotech partners in oncology and autoimmune disease.
United Kingdom ONC

Talk to a Data Expert

Have a question? We'll get back to you promptly.